Drug review fees in Europe to increase

03/11/2013 | In-PharmaTechnologist.com

The European Medicines Agency anticipates that fees for drug reviews will increase approximately 2.6% beginning in April, primarily to account for inflation. The EMA has also announced that it will reduce the current 75% fee reduction it offers for production of orphan drugs and use part of the additional revenue to fund salary and benefit increases.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC